Emilia Development in the First Quarter: Chemovil Repairs the Margin, but Short-Term Debt Rises
Emilia Development opened 2026 with a 2% revenue decline, but profit attributable to shareholders rose 79% as margins improved and Chemovil recovered. The quarter answers part of the open 2025 question, yet cash flexibility still relies on higher short-term bank credit and heavy cash uses.
Emilia Development opened 2026 with a quarter that repairs part of the central concern left by 2025: Chemovil no longer looks like an activity that keeps revenue volume while eroding profit. Consolidated revenue declined by about 2%, but operating profit rose 16% and profit attributable to shareholders rose 79%, mainly because margins improved across the activity areas and Chemovil turned almost flat revenue into a sharp profit rebound. That is a real proof point, not just an accounting headline, but it does not settle the thesis. Part of Chemovil's jump came through other income, Mendelson Infrastructure weakened at the operating-profit line, and the rise in cash during the quarter also relied on a NIS 36.7 million increase in short-term bank credit. The quarter therefore improves the probability that Chemovil's weak 2025 was repairable, but it still does not prove that the parent company can keep upstreaming cash without adding financing pressure. Over the next two to four quarters, the market will get the answer through three numbers: Chemovil's margin without unusual other income, Overseas' profitability under terminal competition, and liquidity after dividends, investments, and short-term debt.
Company Overview
Emilia Development is an industrial holding company, not a single operating industrial business. Its economics are built on three main layers: Mendelson Infrastructure in flow transmission and sanitation, Chemovil in industrial services, and Overseas in logistics services. It also holds additional investments such as Plaziv, Tene and financial assets, but those were not the quarter's center of gravity.
For investors, that means the consolidated line can mislead. A small revenue decline does not mean the whole group weakened, and a strong profit increase does not mean every subsidiary improved equally. The first quarter shows a clear split: Chemovil repairs the margin, Overseas continues to grow revenue and profit, and Mendelson Infrastructure absorbs most of the revenue decline.
The continuity point matters. The prior annual analysis left Emilia entering 2026 with an open question around Chemovil: was the 2025 erosion a cyclical and operational problem, or a signal that the segment struggles to protect earnings quality. The first quarter gives an initial answer in favor of repair, but not yet a full answer for the parent company.
Chemovil Provides the Repair, Mendelson Shows the Group Is Not Moving in One Direction
The number that holds the quarter is not the net-profit increase alone, but its source. Chemovil reported revenue of NIS 172.9 million, almost unchanged from NIS 173.6 million in the comparable quarter, while gross profit rose to NIS 34.9 million from NIS 29.3 million. Gross margin rose to about 20.2% from about 16.9%, and operating profit rose to NIS 16.9 million from NIS 7.1 million.
That is material progress relative to the 2025 problem, when Chemovil kept a large activity base but lost a large part of its profitability. Still, there is a difference between operating repair and fully recurring earnings quality. Chemovil recorded net other income of about NIS 4.7 million in the quarter, compared with about NIS 0.8 million in the comparable quarter. Even excluding that line there is gross-margin improvement, but the operating-profit jump is not entirely a new annualized base.
The acquisition in food-industry raw materials adds an important layer to the thesis. A Chemovil subsidiary completed on March 8, 2026 the acquisition of an import, marketing and sales activity for about NIS 15 million, with contingent consideration that can reach NIS 2.5 million. It is not a large transaction at group level, but it addresses exactly the question that remained open: is Chemovil buying only sales volume, or can it buy an activity that also supports gross profit and cash flow. The current quarter is still too short to decide, because the transaction closed close to period-end.
Mendelson Infrastructure shows the other side of the same quarter. Revenue declined to NIS 238.0 million from NIS 254.0 million, and operating profit declined to NIS 14.3 million from NIS 17.8 million. Gross margin improved, but lower revenue and higher selling and administrative expenses erased most of the benefit. The backdrop includes high interest rates that weigh on some construction-sector customers and hurt payment discipline, alongside the impact of the fighting on part of the group companies. That makes Chemovil's improvement more important: it is not only a positive addition, it is what balances weakness elsewhere.
Overseas provided a steadier quarter. Revenue rose to NIS 98.3 million from NIS 90.4 million, and operating profit rose to NIS 15.3 million from NIS 13.9 million. That is not a Chemovil-style jump, but it continues the 2025 line: logistics still contributes growth and profit. The risk has not disappeared, because terminal competition and port tariff anchors can still pressure prices. For now, the quarter says Overseas is still holding its profit layer.
| Segment | Q1 2026 revenue | Change vs Q1 2025 | Q1 2026 operating profit | What it means |
|---|---|---|---|---|
| Chemovil | NIS 172.9 million | 0.4%- | NIS 16.9 million | Sharp margin repair, but part of profit includes other income |
| Mendelson | NIS 238.0 million | 6.3%- | NIS 14.3 million | Lower revenue and higher expenses pressure profit |
| Overseas | NIS 98.3 million | 8.7%+ | NIS 15.3 million | Continued growth, with resilience still to prove against competition |
Cash Flow Is Stronger, but Some Flexibility Is Bought With Short-Term Credit
Cash flow from operating activities was NIS 74.9 million, compared with NIS 64.0 million in the comparable quarter. The improvement relied on higher profit and lower working-capital needs: receivables declined by NIS 26.4 million and inventory declined by NIS 10.4 million, partly offset by a NIS 14.9 million decline in suppliers. For an operating holding company, that is positive, because it means the profit did not remain entirely on paper.
But all-in cash flexibility after all actual cash uses is narrower. During the quarter, Emilia used NIS 42.6 million for investing activity, including NIS 37.5 million in property and equipment and NIS 15.9 million in intangible assets, partly offset by NIS 9.8 million of proceeds from property and equipment disposals. This includes a NIS 20 million land acquisition in Mendelson Infrastructure and the Chemovil activity acquisition. In addition, the company repaid NIS 22.0 million of long-term loans and NIS 17.5 million of lease principal.
The number that prevents the cash flow from looking too clean is the increase in short-term bank credit. Short-term bank credit rose by a net NIS 36.7 million, mainly at Chemovil for the activity acquisition. After all these movements, cash increased by NIS 27.1 million to NIS 79.2 million, but without the rise in short-term credit the quarter would have looked much less comfortable. This is not an immediate liquidity problem, because management believes that under the scenarios examined, the group is not expected to face difficulty repaying debt or raising cash from the banking system. It is a distinction between strong operating cash flow and full capital-allocation freedom.
Dividends add another cash layer. During and after the period, Plaziv, Mendelson Infrastructure, Overseas and Emilia itself approved distributions. Emilia declared a NIS 5.14 million dividend paid on April 28, 2026, Mendelson Infrastructure paid a NIS 20 million dividend after quarter-end, and Overseas distributed NIS 2.8 million in April and approved an additional NIS 4.15 million distribution in May for payment in June. This supports the ability to move cash up the chain, but the quarter does not include a quarterly solo report. It is therefore still hard to see exactly how much cash remains at the parent level after dividends and debt service.
Conclusion
The first quarter improves Emilia's position more than the revenue decline suggests. Chemovil, the main weak point in 2025, shows real improvement in margin and pre-tax profit, and Overseas continues to contribute growth. Against that stand two frictions: part of Chemovil's profit still needs to prove repeatability, and Mendelson Infrastructure shows that some customers and activity remain under pressure.
The current read is cautiously positive: in the first quarter, Emilia received initial proof that Chemovil can recover, but not full proof that this value is already comfortably accessible at the parent level. All-in cash flexibility after actual cash uses still depends on short-term credit, dividends from subsidiaries, and the ability to keep operating cash flow high while investments, leases and debt repayments continue to leave the cash register.
The rest of 2026 should be treated as a proof year, not a victory year. If Chemovil keeps gross margin high without unusual items, if Overseas maintains profitability despite terminal competition, and if the current ratio decline from 1.64 to 1.55 does not become a trend, the first quarter will look like the start of an earnings-quality recovery. If short-term debt keeps rising to finance acquisitions, inventory or dividends, the market may reinterpret the profit increase as only a partial solution.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.